Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $7.75 and traded as low as $7.17. Bayer Aktiengesellschaft shares last traded at $7.19, with a volume of 507,570 shares traded.
Analysts Set New Price Targets
Separately, Bank of America raised Bayer Aktiengesellschaft from an "underperform" rating to a "neutral" rating in a research report on Friday, September 6th. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company's stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of "Hold".
Get Our Latest Stock Analysis on BAYRY
Bayer Aktiengesellschaft Stock Performance
The company has a 50-day moving average price of $7.75 and a two-hundred day moving average price of $7.51. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $28.25 billion, a P/E ratio of -8.26 and a beta of 1.08.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $0.25 EPS for the quarter, meeting the consensus estimate of $0.25. The company had revenue of $12 billion during the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. On average, equities analysts forecast that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current year.
About Bayer Aktiengesellschaft
(
Get Free Report)
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Further Reading
Before you consider Bayer Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.
While Bayer Aktiengesellschaft currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
